January 18th, 2022 | 16:37 CET
Buy Long-Covid Stock Now? BioNTech, Cardiol, Mainz Biomed
The second trading day this week is characterized by a weak start to trading. In the first two hours, the German indices have clearly lost ground. The leading index DAX is currently trading at 15,776 points, down around 1.05% on the previous day. The MDAX last traded at 34,156 points (-1.38%), TecDAX at 3,498 points (-1.77%) and SDAX at 15,658 points with 1.65% in the red. In the focus of market participants today are repeatedly the shares of vaccine manufacturers, but the trend is now also to the next phase of the Corona situation, the treatment of Long-Covid.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , MAINZ Biomed | NL0015000LC2
Table of contents:
"[...] Having Investors like Robert Friedland and Rob McEwen come in with CVMR and Terra Capital really was terrific. [...]" Terry Lynch, CEO, Power Nickel Inc.
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Sell-off of BioNTech continues
The stock of biotech company BioNTech again led the most executed orders on Tradegate today. At the moment, more than 6,600 transactions were counted. At a price of EUR 157.15, the share is trading 6.21% lower than the previous day, continuing its downward trend. Mainz Biomed can also take a place in the top 5 list with more than 2,400 executed orders. The share is currently trading at EUR 23.00, down 3.32%. Compared to the intraday low at EUR 19.92, the share was able to recover more than EUR 3.00.
Long-Covid share: Cardiol develops therapies for heart problems
The shares of Cardiol Therapeutics continue the price increase of the past days since the opening on the home exchange in Toronto. At CAD 2.91, the stock is trading up 3.2%. The company focuses on the therapy of heart disease and relies on natural active ingredients from the cannabis plant. Clinical trials are expected to confirm the success.
In recent months, reports of heart problems in athletes have increased. According to media reports, the cause of these problems is often related to a Covid-19 infection. Names such as Alphonso Davies (FC Bayern Munich), Arsenal star Pierre-Emerick Aubameyang, Axel Méyé (IR Tangier) and Mario Lemina (OGC Nice) have had to take a break since last week due to heart problems following a Corona infection.
The mentioned top athletes are certainly only the tip of the iceberg and the potential of Long-Covid shares is accordingly high. The experts at GBC Research recommend Cardiol's stock as a buy with a price target of CAD 17.49. Additional analysts recommend the shares. Canaccord with rating 'Buy' and Cantor Fitzgerald with 'Overweight' independently see a price target of USD 8.00 ≈ CAD 10.00.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
